MX2023006785A - Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso. - Google Patents

Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso.

Info

Publication number
MX2023006785A
MX2023006785A MX2023006785A MX2023006785A MX2023006785A MX 2023006785 A MX2023006785 A MX 2023006785A MX 2023006785 A MX2023006785 A MX 2023006785A MX 2023006785 A MX2023006785 A MX 2023006785A MX 2023006785 A MX2023006785 A MX 2023006785A
Authority
MX
Mexico
Prior art keywords
difluoro
solid forms
difluoropropan
fluoropropyl
azetidin
Prior art date
Application number
MX2023006785A
Other languages
English (en)
Inventor
Hans Iding
Francis Gosselin
Alec Fettes
Haiming Zhang
Ngiap- Kie Lim
Paroma Chakravarty
Karthik Nagapudi
Cheol Keun Chung
Jie Xu
Kyle Clagg
Michael Dalziel
Andrew Mcclory(Finado)
Sarah Robinson
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023006785A publication Critical patent/MX2023006785A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En la presente se proveen formas sólidas, sales tales como el Compuesto B, y formulaciones de 3-((1R,3R)-1-(2,6-difluoro-4-((1-( 3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahi dro-2H-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, procesos y síntesis de estos y métodos para su uso en el tratamiento del cáncer.
MX2023006785A 2018-06-21 2020-10-29 Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso. MX2023006785A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687930P 2018-06-21 2018-06-21
US201862719896P 2018-08-20 2018-08-20

Publications (1)

Publication Number Publication Date
MX2023006785A true MX2023006785A (es) 2023-06-20

Family

ID=67441580

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020011531A MX2020011531A (es) 2018-06-21 2019-06-17 Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3 il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3 ,4-b]indol-2-il)-2,2 difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso.
MX2022016065A MX2022016065A (es) 2018-06-21 2020-10-29 Formas solidas de 3 -((1r, 3r)-1-(2,6-difluoro-4 -((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-t etrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden una porcion de fenilo o piridinilo sustituido, incluyendo metodos de uso.
MX2023006785A MX2023006785A (es) 2018-06-21 2020-10-29 Formas solidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3- il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[ 3,4-b]indol-2-il)-2,2- difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos metodos para su uso.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020011531A MX2020011531A (es) 2018-06-21 2019-06-17 Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil )azetidin-3 il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3 ,4-b]indol-2-il)-2,2 difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso.
MX2022016065A MX2022016065A (es) 2018-06-21 2020-10-29 Formas solidas de 3 -((1r, 3r)-1-(2,6-difluoro-4 -((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-t etrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden una porcion de fenilo o piridinilo sustituido, incluyendo metodos de uso.

Country Status (29)

Country Link
US (2) US10954234B2 (es)
EP (2) EP3810283B1 (es)
JP (4) JP6916969B1 (es)
KR (2) KR20230117761A (es)
CN (2) CN117946107A (es)
AU (3) AU2019290545B2 (es)
BR (1) BR112020024073A2 (es)
CA (1) CA3098203A1 (es)
CL (1) CL2020003022A1 (es)
CO (1) CO2020014604A2 (es)
CR (2) CR20230409A (es)
DK (1) DK3810283T3 (es)
ES (1) ES2951829T3 (es)
FI (1) FI3810283T3 (es)
HR (1) HRP20230859T1 (es)
HU (1) HUE064542T2 (es)
IL (1) IL278063A (es)
LT (1) LT3810283T (es)
MX (3) MX2020011531A (es)
PE (1) PE20211207A1 (es)
PH (1) PH12020500676A1 (es)
PL (1) PL3810283T3 (es)
PT (1) PT3810283T (es)
RS (1) RS64429B1 (es)
SG (1) SG11202012171SA (es)
SI (1) SI3810283T1 (es)
TW (1) TW202016098A (es)
UA (1) UA128114C2 (es)
WO (1) WO2019245974A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012171SA (en) 2018-06-21 2021-01-28 Hoffmann La Roche Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
JP2023525022A (ja) * 2020-05-07 2023-06-14 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 組み合わせ
US11918561B2 (en) 2020-05-12 2024-03-05 Genentech, Inc. Treatment of breast cancer using combination therapies comprising GDC-9545 and a CDK4/6 inhibitor
CN115836068A (zh) * 2020-05-15 2023-03-21 先声药业有限公司 吡咯烷类化合物及其应用
EP4174059A1 (en) 2020-06-28 2023-05-03 Medshine Discovery Inc. Indazole-fused cyclic compound
MX2022015880A (es) * 2020-06-30 2023-02-27 Genentech Inc Procesos para elaborar compuestos serd tricíclicos que tienen un resto sustituido de fenilo o piridinilo.
WO2022140744A1 (en) * 2020-12-23 2022-06-30 Recurium Ip Holdings, Llc Estrogen receptor modulators
TW202237099A (zh) * 2021-02-16 2022-10-01 美商建南德克公司 使用包含ｇｄｃ－９５４５及帕他色替之組合療法治療乳癌
JP2024506348A (ja) * 2021-02-16 2024-02-13 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５とアベマシクリブ又はリボシクリブとを含む併用療法を使用する乳がんの治療
CN117813288A (zh) 2021-07-15 2024-04-02 西藏海思科制药有限公司 芳氨基衍生物雌激素受体调节剂及其用途
CN114656444A (zh) * 2022-03-04 2022-06-24 河北松辰医药科技有限公司 一种2,2-二氟-1,3-丙基磺酸内酯的合成方法
TW202400141A (zh) 2022-04-28 2024-01-01 瑞士商赫孚孟拉羅股份公司 ３－（（１ｒ，３ｒ）－１－（２，６－二氟－４－（（１－（３－氟丙基）四氫吖唉－３－基）胺基）苯基）－３－甲基－１，３，４，９－四氫－２ｈ－吡啶并［３，４－ｂ］吲哚－２－基）－２，２－二氟丙－１－醇酒石酸鹽之固體形式
CN115872996B (zh) * 2023-02-21 2023-05-05 山东绿叶制药有限公司 一种雌激素受体降解剂化合物及其制备方法和应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7414572L (es) 1973-12-06 1975-06-09 Endo Lab
SE455604B (sv) 1982-06-29 1988-07-25 Stiftelsen Ind Organisk Elektr Sett att framstella fenetylaminer medelst elektrokemisk reduktion
DE3639329C1 (de) 1986-11-18 1988-02-25 Heesemann Karl Masch Bandschleifmaschine
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
RU14873U1 (ru) 2000-06-26 2000-09-10 Закрытое акционерное общество "Патентные услуги" Комбинированная машина непрерывного литья заготовок
EP1347759B1 (en) 2000-12-08 2005-06-29 Smithkline Beecham Corporation Antibacterial compounds
EP1360185B1 (en) 2001-02-12 2005-08-24 Lilly Icos LLC Carboline derivatives
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
EP1670314A4 (en) 2003-09-05 2009-02-25 Sequella Inc METHODS AND COMPOSITIONS INCLUDE DIAMINE AS A NEW THERAPEUTIC FOR TUBERCULOSIS
CN1930162B (zh) 2004-03-11 2010-06-16 埃科特莱茵药品有限公司 四氢吡啶并吲哚衍生物
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
EP1737461B1 (en) 2004-03-15 2012-12-12 PTC Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP1786425A1 (en) 2004-08-02 2007-05-23 SmithKline Beecham Corporation Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
EP1968934A4 (en) 2006-01-02 2014-02-26 Hetero Drugs Ltd METHOD FOR OBTAINING PURE OSELTAMIVIR
AU2008239598A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
AU2009242279B2 (en) 2008-04-29 2012-08-30 Novartis Ag Spiro-indole derivatives for the treatment of parasitic diseases
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
US20110195929A1 (en) 2008-08-05 2011-08-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
DE102009006545B4 (de) 2009-01-29 2017-08-17 Epcos Ag Überspannungsableiter und Anordnung von mehreren Überspannungsableitern zu einem Array
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
TW201100428A (en) 2009-03-31 2011-01-01 Arqule Inc Substituted indolo-piperidine compounds
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
CA2999345A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
US8697662B2 (en) 2009-05-27 2014-04-15 Ptc Therapeutics, Inc. Methods for treating Kaposi sarcoma
WO2010138706A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2011150162A1 (en) 2010-05-27 2011-12-01 Ptc Therapeutics, Inc. Methods for treating viral conditions
CN102939287B (zh) 2010-06-10 2016-01-27 塞拉根制药公司 雌激素受体调节剂及其用途
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
US9540361B2 (en) 2010-12-24 2017-01-10 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
EP2828385B1 (en) 2012-03-23 2018-02-07 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
AP2014007906A0 (en) 2012-03-23 2014-08-31 Novartis Ag Chemical process for preparing spiroindolones and intermediates thereof
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
DK2997033T3 (da) 2013-05-17 2018-01-29 Merck Sharp & Dohme Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere
LT3004090T (lt) 2013-05-28 2018-01-10 Astrazeneca Ab Cheminiai junginiai
WO2014205138A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
KR102266696B1 (ko) 2013-10-28 2021-06-21 드렉셀유니버시티 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
AU2014358850A1 (en) 2013-12-06 2016-06-16 F. Hoffmann-La Roche Ag Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
SG11201607339VA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Methods and compositions for modulating estrogen receptor mutants
WO2015136016A2 (en) 2014-03-13 2015-09-17 F. Hoffmann-La Roche Ag Therapeutic combinations with estrogen receptor modulators
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
US20160175284A1 (en) 2014-12-18 2016-06-23 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR20230113416A (ko) * 2014-12-18 2023-07-28 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체조절제 및 이의 용도
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
KR20180071274A (ko) 2015-10-01 2018-06-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
CN113788826A (zh) * 2016-02-01 2021-12-14 武田药品工业株式会社 共晶体
BR112018015419B1 (pt) 2016-02-05 2024-01-30 Inventisbio Llc Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica
CN109843882A (zh) * 2016-06-16 2019-06-04 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
JP7018026B2 (ja) * 2016-06-16 2022-02-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ヘテロアリールエストロゲン受容体モジュレーター及びその使用
SG11202012171SA (en) 2018-06-21 2021-01-28 Hoffmann La Roche Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use

Also Published As

Publication number Publication date
HUE064542T2 (hu) 2024-03-28
JP2021522312A (ja) 2021-08-30
KR20230117761A (ko) 2023-08-09
WO2019245974A1 (en) 2019-12-26
EP4295845A3 (en) 2024-02-28
AU2022202967B2 (en) 2024-02-22
UA128114C2 (uk) 2024-04-10
ES2951829T3 (es) 2023-10-25
IL278063A (en) 2020-11-30
FI3810283T3 (fi) 2023-08-11
HRP20230859T1 (hr) 2023-11-10
US20200002331A1 (en) 2020-01-02
EP3810283A1 (en) 2021-04-28
BR112020024073A2 (pt) 2021-02-17
US10954234B2 (en) 2021-03-23
MX2020011531A (es) 2021-03-25
PE20211207A1 (es) 2021-07-05
MX2022016065A (es) 2023-02-02
JP6916969B1 (ja) 2021-08-11
AU2022202967A1 (en) 2022-05-26
JP2024054111A (ja) 2024-04-16
CR20230409A (es) 2023-09-25
CO2020014604A2 (es) 2020-12-10
WO2019245974A8 (en) 2020-11-05
CA3098203A1 (en) 2019-12-26
LT3810283T (lt) 2023-08-25
AU2019290545B2 (en) 2022-04-14
TW202016098A (zh) 2020-05-01
KR20210022701A (ko) 2021-03-03
DK3810283T3 (en) 2023-08-21
JP2021191750A (ja) 2021-12-16
CN112437685A (zh) 2021-03-02
US20220041587A1 (en) 2022-02-10
US11780834B2 (en) 2023-10-10
AU2019290545A1 (en) 2020-11-19
PL3810283T3 (pl) 2023-10-16
PH12020500676A1 (en) 2021-06-14
CN117946107A (zh) 2024-04-30
EP3810283B1 (en) 2023-06-14
SI3810283T1 (sl) 2023-10-30
RS64429B1 (sr) 2023-09-29
JP2021191751A (ja) 2021-12-16
EP4295845A2 (en) 2023-12-27
CR20200621A (es) 2021-02-03
KR102564647B1 (ko) 2023-08-11
SG11202012171SA (en) 2021-01-28
PT3810283T (pt) 2023-08-18
AU2023229513A1 (en) 2023-10-05
CL2020003022A1 (es) 2021-06-04

Similar Documents

Publication Publication Date Title
MX2022016065A (es) Formas solidas de 3 -((1r, 3r)-1-(2,6-difluoro-4 -((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-t etrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos triciclicos fusionados que comprenden una porcion de fenilo o piridinilo sustituido, incluyendo metodos de uso.
MY144483A (en) 1,2,3,4-tetrasubstituted indole for the treatment of respiratory diseases
MX2020001302A (es) Procesos para preparar compuestos de pirrolidina.
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
TW200621715A (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MX2010005556A (es) Procedimiento para la fabricacion de un derivado de indolinona.
MX2009007337A (es) Indazoles sustituidos con 5-piridinona.
MX2021001690A (es) Indoles sustituidos y metodos de uso de los mismos.
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
MX2021011723A (es) Ligandos de pseudocinasa tyk2.
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
TW200833660A (en) Synthesis of pyrrolidine compounds
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2023008330A (es) Agonistas del receptor dual gip/glp-1 de molécula pequeña, composiciones farmacéuticas y preparación de las mismas para usarse en el tratamiento de trastornos metabólicos y hepáticos.
IN2012DN03844A (es)
MXPA05007339A (es) Derivados de alfa-aminoamida utiles como agentes antimigranosos.
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
MX2022007988A (es) Formas cristalinas de (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
UY34170A (es) Formas cristalinas de 2,2,2-trifluoro-N-[(1R,2S)-1-[1-(4-fluorofenil)indazol-5-il]oxi-1-(3-metoxifenil)propan-2-il]acetamida
AR114974A1 (es) Procesos para preparar compuestos tricíclicos fusionados que comprenden un resto piridinilo o fenilo sustituido, incluidos métodos para su uso
WO2019018592A3 (en) PROCESS FOR THE PREPARATION OF N- ((1R, 2S, 5R) -5- (TERT-BUTYLAMINO) -2 - ((S) -3- (7-TERT-BUTYLPYRAZOLO [1,5-A]] 1,3 , 5] triazin-4-ylamino) -2-oxopyrrolidin-1-yl) cyclohexyl) acetamide
TN2009000069A1 (en) Polymorph of (r) -3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azoni a-bicylco-[2.2.2]octane bromide
WO2018226178A3 (en) (E) -1- (4-CINNAMOYL-PHENYL) -1H-PYRROLE-2,5-DIONE DERIVATIVES WITH ANTI-CANCER EFFECT